The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem. 

Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.

Entyvio strong again for Japanese firm as it raises net profit forecast on lower tax costs. Meanwhile, 'Wave 1' pipeline projects are progressing, with simultaneous development in major markets a key goal. 

Japanese major sheds further non-core assets as it continues to focus on innovation and pay down debt following the Shire acquisition.